Intensity Therapeutics(INTS) - 2024 Q4 - Annual Results

Exhibit 99.1 Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update Shelton, Conn., March 13, 2025 – Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces 2024 year-end financial results and provides a corporate updat ...